Rapport Therapeutics CFO Troy Ignelzi buys $143,550 in company stock

Troy A. Ignelzi, Chief Financial Officer of Rapport Therapeutics, Inc. (NASDAQ:RAPP), recently acquired shares of the company’s common stock. The transaction, dated October 21, 2026, involved the purchase of 5,500 shares.

Mr. Ignelzi acquired the shares at a price of $26.1 per share, resulting in a total transaction value of $143,550. The purchase comes as the stock trades near its 52-week low of $23.75, with shares currently at $25.06. Following this purchase, Mr. Ignelzi directly beneficially owns 15,500 shares of Rapport Therapeutics common stock. The company maintains a strong balance sheet with a current ratio of 15.72 and holds more cash than debt, according to InvestingPro analysis, which currently values the stock as undervalued. Investors can access 10 additional ProTips and comprehensive financial metrics on the platform.

In other recent news, Rapport Therapeutics has seen a series of updates from various analyst firms regarding its stock price target and clinical trial results. Jones Trading raised its price target for Rapport Therapeutics to $82, citing positive clinical trial results for the RAP-219 drug candidate in both FOS and BPM indications. Guggenheim also increased its price target to $70, highlighting successful Phase 2 trial results in bipolar mania, which met both primary and secondary endpoints. Meanwhile, Raymond James raised its price target to $86, following encouraging data from the company’s bipolar disorder trial and increased its probability of success for the bipolar program.

On the other hand, Wells Fargo lowered its price target to $50, maintaining an Overweight rating but expressing concerns about potential treatment discontinuations observed in the FOS Phase 2 trial. Despite the mixed reactions, the overall sentiment among analysts appears positive, with multiple firms maintaining a Buy or Strong Buy rating. These developments reflect the ongoing evaluation of Rapport Therapeutics’ clinical programs and their potential impact on the company’s future prospects.